Brief: Nuvectis Pharma Announces Orphan Drug Tag Granted By FDA For The Treatment Of Cholangiocarcinoma
17/08/2023 13:09
Aug 17 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED
BY THE
FDA TO NXP800 FOR THE TREATMENT OF CHOLANGIOCARCINOMA
Source text for Eikon: ID:nGNE6wkn8q
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin